CCS
CTIC

Crosspoint Capital Strategies’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Crosspoint Capital Strategies’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-2,500
Closed -$59K – 865
2014
Q4 		$59K Hold
2,500
– – 0.02% 343
2014
Q3 		$61K Hold
2,500
– – 0.05% 201
2014
Q2 		$64K Hold
2,500
– – 0.02% 223
2014
Q1 		$85K Hold
2,500
– – 0.03% 205
2013
Q4 		$95K Buy
+2,500
New +$45.5K 0.03% 201

Other funds holding CTIC

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return

Crosspoint Capital Strategies's CTIC Position: Q1 2015 in Review

Crosspoint Capital Strategies sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2015, closing a stake of 2,500 shares — an estimated $59K sold.

Crosspoint Capital Strategies first reported a position in CTIC in Q4 2013 and held it in 5 quarters. The position peaked at $95K in Q4 2013. 98 funds tracked by Wall St. Rank hold CTIC as of Q1 2015.

  • Crosspoint Capital Strategies reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2015 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 2,500 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2015, an estimated $59K.
  • Crosspoint Capital Strategies first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2013 and held it in 5 quarters.
  • Crosspoint Capital Strategies's CTI BioPharma Corp. (DE) Common Stock position peaked at $95K in Q4 2013.
  • 98 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2015.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2015, filed 18 May 2015.